TEVANYSEPharmaceutical PreparationsFiscal year ends December 31

TEVA PHARMACEUTICAL INDUSTRIES LTD

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026

$41.31−0.19 (-0.46%)

Close on Oct 19, 2026

Market cap: $48.13B
P/E (TTM): 68.9
Dividend yield: –

TEVA PHARMACEUTICAL INDUSTRIES LTD income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31
Revenue	17,258	16,544	15,846	14,925	15,878	16,659	16,887	18,271	21,853	21,903	19,652	20,272	20,314	20,317	18,312	16,121	16,121	11,085	9,408
Cost of Revenue	8,320	8,481	8,200	7,952	8,284	8,933	9,351	9,975	11,237	10,250	8,296	9,216	9,607	9,665	8,797	7,056	6,532	5,117	4,531
Gross Profit	8,938	8,064	7,645	6,973	7,594	7,726	7,537	8,296	10,615	11,653	11,356	11,056	10,707	10,652	9,515	9,065	7,367	5,968	4,877
Research & Development	1,013	998	953	838	967	997	1,010	1,213	175	422	35	0	5.00	73	15	951	825	786	581
Selling, General & Admin	3,973	3,702	3,498	3,445	3,528	3,671	3,806	4,214	4,846	4,973	4,838	5,078	5,319	5,117	4,410	3,833	3,499	2,511	1,901
Selling & Marketing	2,686	2,541	2,336	2,265	2,429	2,498	2,614	2,916	3,395	3,583	3,478	3,861	4,080	3,879	3,478	2,968	2,676	1,842	1,264
General & Administrative	1,287	1,161	1,162	1,180	1,099	1,173	1,192	1,298	1,451	1,390	1,360	1,217	1,239	1,238	932	865	823	669	637
Advertising Expenses	309	259	162	168	246	225	213	256	318	312	297	302	321	337	248	243	212	87	–
Operating Income	2,157	-303	433	-2,197	1,716	-3,572	-443	-1,637	-17,484	2,154	3,352	3,951	1,649	2,205	3,109	3,871	2,405	1,145	2,395
Interest Expense	916	1,002	1,029	930	891	901	822	920	875	546	270	300	314	355	234	202	230	201	–
Income from Equity Investments	15	1.00	2.00	21	9.00	138	-13	-71	-3.00	8.00	-121	-5.00	-40	-46	-61	-24	-33	-1.00	-3.00
Other Non-Operating Income	-934	-981	-1,057	-966	-1,058	-834	-822	-959	-895	-1,330	-1,000	-313	-399	-386	-153	-225	-202	-345	-91
Merger & Restructuring Charges	225	74	111	146	133	120	199	488	535	245	183	246	201	221	192	260	90	0	–
Asset Impairment Charges	0	1,280	700	2,045	584	6,546	1,778	5,621	17,100	1,645	361	387	524	1,071	201	124	110	107	0
Gain (Loss) on Sale of Assets	-22	15	3.00	46	7.00	11	-1.00	67	1,083	720	–	–	–	–	–	–	–	–	–
Legal Settlements	-467	-761	-1,043	-2,082	-717	-60	1,178	1,208	-500	-899	–	–	-1,029	-45	-441	-2.00	-434	-17	–
Pretax Income	1,223	-1,284	-624	-3,163	658	-4,406	-1,265	-2,596	-18,379	824	2,352	3,638	1,250	1,819	2,956	3,646	2,203	800	2,304
Income Tax Expense	-180	676	-7.00	-643	211	-168	-278	-195	-1,933	521	634	591	-43	-137	127	283	166	184	386
Net Income incl. Noncontrolling Interests	1,418	-1,959	-615	-2,499	456	-4,099	-1,000	-2,472	-16,449	311	1,597	3,042	1,253	1,910	2,768	3,339	2,004	615	1,915
Minority Interest in Earnings	7.00	-320	-56	-53	39	-109	-2.00	-322	-184	-18	9.00	-13	-16	-53	9.00	8.00	4.00	6.00	1.00
Net Income	1,410	-1,639	-559	-2,446	417	-3,990	-999	-2,150	-16,265	329	1,588	3,055	1,269	1,963	2,759	3,331	2,000	609	1,914
Preferred Dividends	–	–	–	–	–	–	–	249	260	261	15	0	–	–	–	–	–	–	–
Net Income to Common	1,410	-1,639	-559	-2,446	417	-3,990	-999	-2,399	-16,525	68	1,573	3,055	1,269	1,963	2,759	3,375	2,001	614	–
EPS (Basic)(per share)	1.23	-1.45	-0.50	-2.20	0.38	-3.64	-0.91	-2.35	-16.26	0.07	1.84	3.58	1.49	2.25	3.10	3.72	2.29	0.78	2.49
EPS (Diluted)(per share)	1.21	-1.45	-0.50	-2.20	0.38	-3.64	-0.91	-2.35	-16.26	0.07	1.82	3.56	1.49	2.25	3.09	3.67	2.23	0.75	2.36
Shares Outstanding (Basic, Weighted)(shares)	1,145	1,131	1,119	1,110	1,102	1,095	1,091	1,021	1,016	0.00	855	853	849	872	890	896	872	780	768
Shares Outstanding (Diluted, Weighted)(shares)	1,163	1,131	1,119	1,110	1,107	1,095	1,091	1,021	1,016	0.00	864	858	850	873	893	921	896	820	830
Dividend per Share(per share)	–	–	–	–	–	–	0.00	0.00	0.85	1.36	1.36	1.34	1.28	1.03	0.89	0.74	0.61	0.50	–
EBITDA	3,159	756	1,586	-889	3,046	-2,015	1,279	205	-15,372	3,678	4,660	5,459	3,291	3,913	4,178	4,848	3,313	1,635	2,894

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 64.4%
Operating margin: 11.4%
Net margin: 5.0%
Return on equity, FY2025: 21.2%

Financial strength

Current ratio: 0.88
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 23.4%

Valuation

P/E ratio: 68.9
Price to sales: 3.41
Price to book: 6.21
Dividend yield: –